Pam Cheng - AstraZeneca PLC EVP Board

All Insiders . Germany . 
Stock . AstraZeneca PLC . Stakeholders . Insider . Pam Cheng
ZEG Stock  EUR 128.40  2.75  2.10%   

Insider

Pam Cheng is EVP Board of AstraZeneca PLC
Age 52
Phone44 20 3749 5000
Webhttps://www.astrazeneca.com

AstraZeneca PLC Management Efficiency

The company has return on total asset (ROA) of 0.0555 % which means that it generated a profit of $0.0555 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0863 %, meaning that it generated $0.0863 on every $100 dollars invested by stockholders. AstraZeneca PLC's management efficiency ratios could be used to measure how well AstraZeneca PLC manages its routine affairs as well as how well it operates its assets and liabilities.
AstraZeneca PLC has accumulated 22.96 B in total debt with debt to equity ratio (D/E) of 179.6, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. AstraZeneca PLC has a current ratio of 0.74, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist AstraZeneca PLC until it has trouble settling it off, either with new capital or with free cash flow. So, AstraZeneca PLC's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like AstraZeneca PLC sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for AstraZeneca to invest in growth at high rates of return. When we think about AstraZeneca PLC's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Andr GerondeauMeli Hotels International
N/A
Eivind KallevikNorsk Hydro ASA
56
William IIReliance Steel Aluminum
55
Pal KildemoNorsk Hydro ASA
39
Lourdes RipollMeli Hotels International
N/A
Arthur AjemyanReliance Steel Aluminum
47
Erik FallstromSIVERS SEMICONDUCTORS AB
56
Angel NaveirasMeli Hotels International
Vandy LuptonReliance Steel Aluminum
N/A
AnneLene MidseimNorsk Hydro ASA
55
Jeffrey DurhamReliance Steel Aluminum
60
Dag SigurdSIVERS SEMICONDUCTORS AB
73
Harry KanwarSuperior Plus Corp
N/A
Patric ErlandssonSIVERS SEMICONDUCTORS AB
51
Therese HolmNorsk Hydro ASA
N/A
Hilde NordhNorsk Hydro ASA
54
Ingrid EngstromSIVERS SEMICONDUCTORS AB
59
Stephane BaosMeli Hotels International
N/A
Paul WartonNorsk Hydro ASA
62
Michael ShanleyReliance Steel Aluminum
65
FCA FCASuperior Plus Corp
68
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom. AstraZeneca PLC operates under Drug Manufacturers - Major classification in Germany and is traded on Frankfurt Stock Exchange. It employs 64400 people. AstraZeneca PLC (ZEG) is traded on Frankfurt Exchange in Germany and employs 83,500 people.

Management Performance

Return On Equity0.0863
Return On Asset0.0555

AstraZeneca PLC Leadership Team

Elected by the shareholders, the AstraZeneca PLC's board of directors comprises two types of representatives: AstraZeneca PLC inside directors who are chosen from within the company, and outside directors, selected externally and held independent of AstraZeneca. The board's role is to monitor AstraZeneca PLC's management team and ensure that shareholders' interests are well served. AstraZeneca PLC's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AstraZeneca PLC's outside directors are responsible for providing unbiased perspectives on the board's policies.
Marc Dunoyer, CEO Officer
Chris Sheldon, Head Relations
Pam Cheng, EVP Board
MBA DVM, CEO Director
Gonzalo Vina, Head Relations
Aradhana MD, CFO Director
Menelas Pangalos, EVP Board
Katarina Ageborg, Chief Sustainability
Jeffrey Pott, G Officer
Ruud Dobber, Exec Unit

AstraZeneca Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is AstraZeneca PLC a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity0.0863
Return On Asset0.0555
Profit Margin0.07 %
Operating Margin0.20 %
Current Valuation228.75 B
Shares Outstanding1.55 B
Shares Owned By Insiders0.22 %
Shares Owned By Institutions47.60 %
Price To Earning38.93 X
Price To Book6.17 X

Currently Active Assets on Macroaxis

CCitigroup
GMGeneral Motors
FFord Motor
GMGeneral Motors
VVisa Class A

Other Information on Investing in AstraZeneca Stock

AstraZeneca PLC financial ratios help investors to determine whether AstraZeneca Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in AstraZeneca with respect to the benefits of owning AstraZeneca PLC security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY